In the News
MSN: Transforming sepsis care: How host-response technology enables rapid, actionable diagnosis
From the MSN article by Omar Alhassan Sepsis remains one of the most urgent clinical emergencies in modern healthcare. Each hour of delayed targeted treatment significantly increases patient mortality. For decades, intensive care and emergency clinicians have struggled with the critical challenge of distinguishing sepsis from non-infectious systemic inflammation. Conventional...
Rollie Carlson Discusses Host Response Testing Gains Attention in Sepsis Diagnosis and Antibiotic Stewardship
Excerpt from a discussion with Tero Vesalainen from CLPMag. A recent poll highlights growing interest in host response testing for sepsis. Immunexpress CEO Rollie Carlson discusses the findings and the future of rapid diagnostics. In a recent poll conducted by Immunexpress following a Sepsis Alliance webinar, 73% of healthcare professionals and patient...
Host-Response Sepsis Diagnostic Test Demonstrating High Predictive Probability of Sepsis – Dr. Prashant Wani
https://vimeo.com/1112436851?share=copy
The Medical Podcast: Sepsis, Speed, and Saving Lives with Dr. Rolland Carlson
Podcast summary: Dr. Rolland “Rollie” Carlson, CEO of Immunexpress is a veteran of the molecular diagnostics space. With over 25 years of leadership across Abbott, WaferGen, Asuragen, and more, Rollie is now focused on solving one of healthcare’s most urgent crises: Sepsis. In this episode, we explore why sepsis, despite...
Immunexpress CEO Rollie Carlson was a panelist at The State of Precision Medicine 2025 from @Inside_PM.
In case you didn’t have a chance to tune in, you can find the archived recordings here: https://webinars.liebertpub.com/e/The-State-of-Precision-Medicine-2025
Interview with Dr. Rollie Carlson on NPR’s Bio Tech Nation
Rollie’s interview with Moira Gunn of NPR Bio Tech Nation has been published. You can listen to the interview here: https://www.biotechnation.com/episodes/dr-rollie-carlson-ceo-immunexpress
“Immunexpress Nabs 510(k) Clearance for EDTA Blood-Compatible Cartridges”
Via 360Dx, " Jan 04, 2024 | staff reporter NEW YORK – Immunexpress announced Thursday that it has secured US Food and Drug Administration 510(k) clearance for ethylenediaminetetraacetic acid (EDTA) blood-compatible cartridges for use with the firm's SeptiCyte Rapid test to differentiate sepsis from infection-negative systemic inflammation. Read the rest here: 360Dx
Rollie Carlson on How Cross-Training and Extreme Ownership Help You Advance Your Career
Immunexpress CEO Rollie Carlson recently appeared on the Mastering Medical Device podcast. Rollie Calrson is the CEO of Immunexpress, a company that is pioneering technology that can rapidly detect sepsis. Rollie contributed to the success of Abbott Laboratories for 20 years, starting off in R&D, then transitioning to leadership positions...
“Improving Outcomes For Patients With Sepsis” — Interview from Progress, Potential & Possibilities
https://www.youtube.com/watch?v=hv-Oy98PA6w "Today we have the honor of being joined by Dr Roland Carlson, who is the Chief Executive Officer of Immuneexpress which is a Seattle-based molecular diagnostic company they're committed to improving the outcomes for patients suspected of having sepsis and their FDA-cleared SeptiCyte technology is focused on rapidly quantifying...
Rollie Carlson joins the Med-Tech podcast to discuss early diagnosis of sepsis
Med-Tech's Ian Bolland interviewed Rollie Carlson, CEO of Immunexpress, about the challenges of diagnosing sepsis and the technology that is being developed to tackle it. https://soundcloud.com/medtalkpodcast/developing-technology-for-faster-sepsis-diagnosis
PodcastDX: Richard Brandon on Sepsis Rapid Test
Listen to the podcast: PodcastDX.com, episode S.14/E.19 Sepsis Rapid Test Show notes from the podcast Sepsis Rapid Test This week we will discuss a new rapid response test for Sepsis with one of the developers, Richard Brandon. Sepsis describes a syndrome that occurs when severe infection results in critical illness...
In the News: Why Better Sepsis Diagnosis Results in Better Outcomes
In Clinical Lab Products, Silvia Cermelli, PhD, and Prashant Wani, PhD say "The delay in sepsis diagnosis not only increases the risk of dying by as much as 8% every hour, but misdiagnosis leads to unnecessary use of strong antibiotic therapies causing health-related burdens on patients and economic burdens on...